| A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2511 in Participants With Early Alzheimer's Disease (AD) (NCT07768592) | Eisai Inc. | 2026-10-15 |
| A Study to Assess Potential Drug-Drug Interactions of E2086 in Healthy Participants (NCT07766369) | Eisai Inc. | 2026-08-12 |
| A Retrospective Database Study for the Development and Validation of Algorithms for Intracerebral Hemorrhage and Seizures in Alzheimer's Disease (NCT07723950) | Eisai Inc. | 2026-07-30 |
| A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy (NCT07493265) | Eisai Inc. | 2026-03-26 |
| A Study to Determine the Metabolism and Excretion of [14C]E2086 in Healthy Male Participants (NCT07308236) | Eisai Inc. | 2025-12-31 |
| A Study of Oral E1018 in Healthy Adult Participants (NCT06854042) | Eisai Inc. | 2025-02-26 |
| A Study to Assess the Pregnancy Outcome in Women Exposed to Dayvigo® During Pregnancy Compared to an Unexposed Control Population (NCT06744673) | Eisai Inc. | 2025-01-03 |
| A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease (NCT06602258) | Eisai Inc. | 2024-09-30 |
| A Study of E2086 in Healthy Adult Participants (NCT06481488) | Eisai Inc. | 2024-06-25 |
| A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants (NCT05745207) | Eisai Inc. | 2023-02-20 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of E2025 in Healthy Participants (NCT05726851) | Eisai Inc. | 2023-02-06 |
| A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants (NCT05533801) | Eisai Inc. | 2022-09-06 |
| A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors (NCT05091346) | Eisai Inc. | 2021-10-27 |
| A Study of Subcutaneous Lecanemab in Healthy Participants (NCT05045716) | Eisai Inc. | 2021-09-07 |
| A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study) (NCT05137847) | Eisai Inc. | 2021-05-24 |
| A Study to Evaluate Lemborexant in Milk of Healthy Lactating Women (NCT04890561) | Eisai Inc. | 2021-05-17 |
| A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma (NCT04763408) | Eisai Inc. | 2021-04-09 |
| A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology (NCT04764669) | Eisai Inc. | 2021-02-25 |
| A Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Participants With Moderate to Severe Obstructive Sleep Apnea, and in Adult and Elderly Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (NCT04647383) | Eisai Inc. | 2021-01-06 |
| A Study to Assess the Safety and Tolerability of E2730 After Multiple Dose and the Food Effect After Single Dose in Healthy Participants (NCT04676685) | Eisai Inc. | 2020-12-16 |
| A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome (NCT04572243) | Eisai Inc. | 2020-09-23 |
| A Study to Assess the Safety and Tolerability of E2511 in Healthy Participants (NCT04547361) | Eisai Inc. | 2020-09-14 |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types (NCT04300556) | Eisai Inc. | 2020-08-06 |
| AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (NCT04468659) | Eisai Inc. | 2020-07-14 |
| A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer (NCT04288089) | Eisai Inc. | 2020-04-01 |
| A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma (NCT04154189) | Eisai Inc. | 2020-03-23 |
| Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101 (NCT04144140) | Eisai Inc. | 2020-02-24 |
| A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102 (NCT04109092) | Eisai Inc. | 2020-02-13 |
| A Study to Assess Safety, Tolerability, Pharmacokinetics (PK), Immunogenicity, and Pharmacodynamics (PD) of Intravenous Infusions of E2814 in Healthy Participants (NCT04231513) | Eisai Inc. | 2019-12-16 |
| A Study to Determine the Metabolism and Elimination of [14C]E2027 in Healthy Male Participants (NCT04023877) | Eisai Inc. | 2019-07-18 |
| A Study to Evaluate Next-Dose Transition From Zolpidem to Lemborexant (LEM) for the Treatment of Insomnia (NCT04009577) | Eisai Inc. | 2019-07-15 |
| A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor (NCT04008797) | Eisai Inc. | 2019-07-11 |
| A Food-Effect Study of E7386 in Healthy Participants (NCT03996226) | Eisai Inc. | 2019-06-07 |
| A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy (NCT04015141) | Eisai Inc. | 2019-05-31 |
| A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease (NCT03887455) | Eisai Inc. | 2019-03-27 |
| A Study to Evaluate the Pharmacodynamic Activity of E2082 in Adult Participants With Photosensitive Epilepsy (NCT03686033) | Eisai Inc. | 2018-10-31 |
| Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials (NCT03477175) | Eisai Inc. | 2018-08-16 |
| A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants (NCT03627936) | Eisai Inc. | 2018-08-07 |
| A Study to Evaluate the Pharmacodynamic Activity of E2730 in Adult Participants With Photosensitive Epilepsy (NCT03603639) | Eisai Inc. | 2018-07-27 |
| A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular Carcinoma (NCT03663114) | Eisai Inc. | 2018-07-02 |
| Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) (NCT03517449) | Eisai Inc. | 2018-06-11 |
| Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy Bodies (NCT03467152) | Eisai Inc. | 2018-05-04 |
| Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC) (NCT03433703) | Eisai Inc. | 2018-04-26 |
| Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS) (NCT03441360) | Eisai Inc. | 2018-04-17 |
| A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer (NCT03583944) | Eisai Inc. | 2018-03-28 |
| Study of Lemborexant-Alcohol Interaction in Healthy Subjects (NCT03483636) | Eisai Inc. | 2018-03-12 |
| Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors (NCT03245450) | Eisai Inc. | 2018-03-05 |
| Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects With Mild Obstructive Sleep Apnea (NCT03471871) | Eisai Inc. | 2018-02-21 |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730 in Healthy Participants (NCT03451890) | Eisai Inc. | 2018-02-09 |
| Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment (NCT03443063) | Eisai Inc. | 2018-02-07 |
| Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy Subjects (NCT03451110) | Eisai Inc. | 2018-02-05 |
| Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects (NCT03440424) | Eisai Inc. | 2018-01-26 |
| A Study to Evaluate the Food-Effect of H3B-6527 (NCT03424577) | Eisai Inc. | 2017-12-27 |
| A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid Tumors (NCT03386942) | Eisai Inc. | 2017-11-28 |
| Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors (NCT03245151) | Eisai Inc. | 2017-11-16 |
| Study to Evaluate Bioavailability of a Single 12 mg Dose of Perampanel for Three Intravenous Infusion Durations Relative to a Single 12 mg Perampanel Oral Tablet in Healthy Subjects (NCT03376997) | Eisai Inc. | 2017-11-08 |
| Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years (NCT03338296) | Eisai Inc. | 2017-09-28 |